title: Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor.
abstract: BACKGROUND
  It is unknown whether chronic erythropoietin (EPO) treatment is able to normalize hemoglobin (Hb) levels and ameliorate cardiac remodeling avoiding blood transfusions in uremic blood transfusion-dependent patients with beta-thalassemia minor (beta-thal).
  
  
  METHODS
  In 12 hemodialysis (HD) patients with beta-thal, requiring blood transfusions despite EPO therapy, we planned to increase Hb levels up to the target levels (11-12 g/dl) within a one-year period by administering progressively higher doses of EPO (correction phase). We also planned to maintain the Hb target for an additional year (maintenance phase).
  
  
  RESULTS
  In the year before the study, patients required 3.3 +/- 0.9 units of packed red blood cells. At baseline, the Hb level obtained with an EPO dose of 212 +/- 73 U/kg/week i.v. was 8.2 +/- 0.8 g/dl. The EPO dose was gradually increased within the first year up to 458 +/- 78 U/kg/week at month 12 (correction phase) and then significantly tapered down during the maintenance phase (390 +/- 54 U/kg/week at month 24). During the correction phase, the Hb levels markedly increased (11.1 +/- 0.3 g/dl at month 12) and did not change in the maintenance phase. No blood transfusion was required throughout the 2 years of follow-up. Left ventricular (LV) mass index progressively decreased from the basal value of 144 +/- 12 to 124 +/- 11 g/m2 in the first year and normalized in all patients at month 24 (109 +/- 12 g/m2, p < 0.001); this occurred in the absence of any change of LV cavity volume index (<90 ml/m2).
  
  
  CONCLUSIONS
  In HD transfusion-dependent patients with beta-thal, the administration of high EPO dose for 2 years permits the attainment and the maintenance of Hb targets without blood transfusions. This therapeutic approach permits a complete remission of concentric LV hypertrophy without any adverse effects on the vascular system.
authors.affiliation: Solofra County Hospital, Solofra, Italy.
authors.forename: Biagio
authors.initials: B
authors.lastname: Di Iorio
authors.forename: Luca
authors.initials: L
authors.lastname: De Nicola
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Bellizzi
authors.forename: Roberto
authors.initials: R
authors.lastname: Minutolo
authors.forename: Pasquale
authors.initials: P
authors.lastname: Zamboli
authors.forename: Roberto
authors.initials: R
authors.lastname: Rubino
authors.forename: Giorgio
authors.initials: G
authors.lastname: Fuiano
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Conte
mesh_terms: D001803:Blood Transfusion; D004921:Erythropoietin / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006403:Hematologic Tests; D006439:Hemodynamics; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D006435:Renal Dialysis / Q000379:methods*; D016896:Treatment Outcome; D020257:Ventricular Remodeling / Q000187:drug effects; D017086:beta-Thalassemia / Q000628:therapy*
chemical_list: D006454:Hemoglobins; D004921:Erythropoietin